Eight-year outcomes of testosterone suppression plus enzalutamide or a nonsteroidal antiandrogen for metastatic hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304)
Eight-year outcomes of testosterone suppression plus enzalutamide or a nonsteroidal antiandrogen for metastatic hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304). // Annals of Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S0923753426014109?dgcid=rss_sd_all
Eight-year outcomes of testosterone suppression plus enzalutamide or a nonsteroidal antiandrogen for metastatic hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304). Annals of Oncology. https://www.sciencedirect.com/science/article/pii/S0923753426014109?dgcid=rss_sd_all
“Eight-year outcomes of testosterone suppression plus enzalutamide or a nonsteroidal antiandrogen for metastatic hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304).” Annals of Oncology.
@article{article35924,
title = {Eight-year outcomes of testosterone suppression plus enzalutamide or a nonsteroidal antiandrogen for metastatic hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304)},
journal = {Annals of Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S0923753426014109?dgcid=rss_sd_all}
}